Study of the PARP Inhibitor BMN 673 in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in PTEN or PTEN Loss, a Homologous Recombination Defect, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)

Study Drug Administration:

If you are found to be eligible to take part in this study, you will take talazoparib
capsules by mouth 1 time each day. You should take the study drug at about the same time
every day with or without food.

If you miss a dose, you should skip that dose and take your next dose as scheduled. If you
vomit after taking the study drug, do not take another dose to make it up. Wait and take your
next dose as scheduled.

Study Visits:

Each study cycle is 28 days.

During Weeks 1 and 2 of Cycle 1:

- You will have a physical exam.

- Blood (about 4 teaspoons) will be drawn for routine tests.

- Blood (about 2 teaspoons) will be drawn for biomarker and genetic testing.

- During Week 1, urine will be collected for routine tests, including a pregnancy test if
you can become pregnant.

During Weeks 3 and 4 of Cycle 1:

- You will have a physical exam.

- Blood (about 4 teaspoons) will be drawn for routine tests.

- Blood (about 2 teaspoons) will be drawn for biomarker and genetic testing.

- During Week 3, depending on when you are enrolled, you will have a tumor biopsy for PD
testing. The study doctor will discuss this with you.

During Week 1 of Cycles 2 and beyond:

- You will have a physical exam.

- Blood (about 4 teaspoons) and urine will be drawn for routine tests.

During Weeks 2, 3, and 4 of Cycles 2-12:

- Blood (about 2 teaspoons) will be drawn for routine tests.

- During Week 4 only, blood (about 2 teaspoons) will be drawn for biomarker and genetic
testing.

Every 8 weeks for 6 months and then every 12 weeks after that, you will have a CT or MRI scan
to check the status of the disease. If the disease appears to get better, you will have a
repeat scan within 4 weeks.

Starting at Cycle 13:

- Every 4 weeks, blood (about 4 teaspoons) and urine will be collected for routine tests.
°You can perform this test at your local doctor's office and the results will be sent to
the study staff.

- Every 12 weeks, blood (about 2 teaspoons) will be drawn for biomarker and genetic
testing.

- Every 12 weeks, if you can become pregnant, urine collected will also be used for a
pregnancy test.

Length of Treatment:

You may continue taking the study drug for as long as the doctor thinks it is in your best
interest. You will no longer be able to take the study drug if the disease gets worse, if
intolerable side effects occur, or if you are unable to follow study directions.

Your participation on this study will be over after 1 year of follow-up calls.

End-of-Treatment Visit:

Right after your last dose of study drug, you will have an end-of-treatment visit:

- You will have a physical exam.

- Blood (about 6 teaspoons) and urine will be drawn for routine tests and biomarker and
DNA testing.

Follow-Up Visit:

About 30 days after your last dose of study drug:

- Blood (about 4 teaspoons) and urine will be collected for routine tests.

- Blood (about 2 teaspoons) will be drawn for and biomarker and DNA testing.

Long Term Follow-Up:

The study staff will call you to ask how you are doing every 12 weeks for up to 1 year. Each
call should last about 5 minutes.

Inclusion Criteria:

1. Patients with advanced or metastatic cancer that is refractory to standard therapy or
has relapsed after standard therapy.

2. Patients must have one of the following: somatic mutations or deletions in BRCA1 or
BRCA2; genomic alterations in other BRCA pathway genes (subcohorts: a. ATM, b. PALB2,
c. other genes, e.g. Fanconi Anemia genes, ARID1A, MER11, RAD50, NBS1, ATR;
amplification of EMSY); or germline mutation in BRCA1 or BRCA 2 (not breast or ovarian
cancer)

3. Patients must be >/=18 years of age.

4. Patients must have measurable disease by RECIST 1.1.

5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.

6. Adequate organ function as defined: absolute neutrophil count >/=1500/mL; platelets
>/= 100,000/mL; hemoglobin >/= 9 g/dL (or >/=5.6mmol/L); serum creatinine ULN (or GFR >/= 60 ml/min for patients with creatinine >1.5xULN); serum total
bilirubin 1.5xULN); AST(SGOT)
and ALT(SGPT) subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic
range of intended use of anticoagulants; aPTT anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use
of anticoagulants

7. Patients must be >/=4 weeks beyond treatment with any chemotherapy or other
investigational therapy to include hormonal, biological, or targeted agents; or at
least 5 half-lives from hormonal, biological, or targeted agents, whichever is shorter
at the time of treatment initiation.

8. Women of child-bearing potential MUST have a negative serum or urine HCG test unless
prior tubal ligation (>/= 1 year before screening), total hysterectomy or menopause
(defined as 12 consecutive months of amenorrhea). Patients should not become pregnant
or breastfeed while on this study. Sexually active patients must agree to use dual
contraception for the duration of study participation and for 120 days after the last
dose of talazoparib.

9. Ability to understand and willingness to sign informed consent form prior to
initiation of the study and any study procedures

10. Patients need to have biopsiable disease to enroll on cohort 1-2. Patients eligible
for Cohort 3 with a germline BRCA alteration can be enrolled even if they do not have
biopsiable disease.

Exclusion Criteria:

1. Patients who are pregnant or breastfeeding;

2. Prior treatment with a PARP inhibitor;

3. Known Hepatitis B, Hepatitis C or HIV infection;

4. Inability or unwillingness to swallow pills.

5. Active infection requiring intravenous (IV) antibiotics or other uncontrolled
intercurrent illness requiring hospitalization.

6. Any medical condition or diagnosis that would likely impair absorption of an orally
administered drug (e.g. gastrectomy, ileal bypass, chronic diarrhea, gastroparesis).

7. Inability to comply with the study and follow-up procedures.

8. History of CVA, myocardial infarction or unstable angina within the previous 6 months
before starting therapy

9. Has a known additional malignancy that is progressing or requires active treatment.
Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the
skin that has undergone potentially curative therapy or in situ cervical cancer.

10. Has a known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial

11. Has known active central nervous system (CNS) metastases and/or carcinomatous
meningitis. Subjects with previously treated brain metastases may participate provided
they are stable (without evidence of progression by imaging for at least four weeks
prior to the first dose of trial treatment and any neurologic symptoms have returned
to baseline), have no evidence of new or enlarging brain metastases, and are not using
steroids for at least 7 days prior to trial treatment. This exception does not include
carcinomatous meningitis which is excluded regardless or clinical stability.